Merck, Inc.
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- Drug: 2 NRTIs
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 84
- Registration Number
- NCT04375800
- Locations
- 🇺🇸
University of Colorado at Denver ( Site 0108), Aurora, Colorado, United States
🇺🇸Emory Children's Center ( Site 0103), Atlanta, Georgia, United States
🇨🇴Clinica Somer ( Site 1003), Rionegro., Antioquia, Colombia
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
- Conditions
- Pulmonary Hypertension
- Interventions
- Drug: FrespaciguatDrug: Placebo
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT04370873
- Locations
- 🇺🇸
Brigham & Women's Hospital ( Site 0001), Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital ( Site 0005), Boston, Massachusetts, United States
🇲🇩Republican Clinical Hospital of Moldova ( Site 0013), Chisinau, Moldova, Republic of
A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT04317066
- Locations
- 🇯🇵
Okayama University Hospital ( Site 0004), Okayama, Japan
🇯🇵Kindai University Hospital ( Site 0001), Osakasayama, Osaka, Japan
🇯🇵National Hospital Organization Disaster Medical Center ( Site 0007), Tachikawa, Tokyo, Japan
MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT04308304
- Locations
- 🇺🇸
ICON ( Site 0003), Salt Lake City, Utah, United States
🇺🇸Woodland Research Northwest, LLC ( Site 0004), Rogers, Arkansas, United States
🇺🇸iResearch Atlanta ( Site 0005), Decatur, Georgia, United States
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 315
- Registration Number
- NCT04305054
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute ( Site 2009), Los Angeles, California, United States
🇺🇸UCLA Hematology & Oncology ( Site 2004), Los Angeles, California, United States
🇺🇸Providence Saint John's Health Center ( Site 2010), Santa Monica, California, United States
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT04305041
- Locations
- 🇮🇱
Chaim Sheba Medical Center ( Site 1701), Ramat Gan, Israel
🇫🇷A.P.H. Paris, Hopital Saint Louis ( Site 1107), Paris, France
🇫🇷Hopital Saint Andre ( Site 1108), Bordeaux, Gironde, France
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04303156
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Miami, Florida, United States
🇩🇪Charite Research Organisation GmbH ( Site 0003), Berlin, Germany
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT04303169
- Locations
- 🇮🇹
Istituto Europeo di Oncologia ( Site 3301), Milano, Italy
🇮🇹Policlinico Le Scotte - A.O. Senese ( Site 3377), Siena, Italy
🇺🇸The Angeles Clinic and Research Institute ( Site 3009), Los Angeles, California, United States
Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)
- Conditions
- HIV-1 Infection
- Interventions
- Drug: DOR/ISL
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT04295772
- Locations
- 🇺🇸
Emory Children's Center ( Site 1805), Atlanta, Georgia, United States
🇺🇸Johns Hopkins University ( Site 1800), Baltimore, Maryland, United States
🇺🇸Children's National Medical Center ( Site 1816), Washington, District of Columbia, United States
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT04246177
- Locations
- 🇺🇸
University of Cincinnati Medical Center ( Site 0791), Cincinnati, Ohio, United States
🇺🇸The Ohio State University Wexner Medical Center ( Site 0759), Columbus, Ohio, United States
🇨🇳Anhui Provincial Hospital ( Site 0092), Heifei, Anhui, China